A phase III study of ALG-1001 (Luminate) for the treatment of wet age-related macular degeneration

Trial Profile

A phase III study of ALG-1001 (Luminate) for the treatment of wet age-related macular degeneration

Planning
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs ALG 1001 (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2016 This profile has been created from information based on company pipeline (http://www.allegroeye.com/wp-content/uploads/2015/11/Allegro-Luminate-Clinical-Timeline-Nov-23-2015.png).
    • 01 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top